To DNA or not to DNA? That is the question, when it comes to molecular subtyping for the clinic!

Clinical Cancer Research

Volumn 17, Issue 15, 2011, Pages 4959-4964

  Smeets, Serge J ^a   Harjes, Ulrike ^a   Van Wieringen, Wessel N ^a,b   Sie, Daoud ^a   Brakenhoff, Ruud H ^a   Meijer, Gerrit A ^a   Ylstra, Bauke ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; GENOMIC RNA; MICRORNA;

ACCURACY; BREAST CANCER; CANCER GENETICS; CANCER SURVIVAL; CHROMOSOME ABERRATION; CHROMOSOME DUPLICATION; CLASSIFICATION; DIAGNOSTIC ACCURACY; DNA DETERMINATION; GENE DUPLICATION; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENE MUTATION; GENE NUMBER; GENETIC ALGORITHM; GENETIC DATABASE; HETEROZYGOSITY; HUMAN; MOLECULAR GENETICS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RNA ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER VARIATIONS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; PROGNOSIS;

EID: 79960988896     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0462     Document Type: Review

References (32)

1. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:1180-4. (Pubitemid 41258223)
2. Bell DW. Our changing view of the genomic landscape of cancer. J Pathol 2010;220:231-43.
3. Sotiriou C, Piccart MJ. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat Rev Cancer 2007;7:545-53. (Pubitemid 46985399)
4. Weigelt B, Mackay A, A'hern R, Natrajan R, Tan DS, Dowsett M, et al. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol 2010;11:339-49.
5. Chin SF, Teschendorff AE, Marioni JC, Wang Y, Barbosa-Morais NL, Thorne NP, et al. High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol 2007;8:R215.
6. Fridlyand J, Snijders AM, Ylstra B, Li H, Olshen A, Segraves R, et al. Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer 2006;6:96.
7. Russnes HG, Vollan HK, Lingjaerde OC, Krasnitz A, Lundin P, Naume B, et al. Genomic architecture characterizes tumor progression paths and fate in breast cancer patients. Sci Transl Med 2010;2:38ra47.
8. Habermann JK, Doering J, Hautaniemi S, Roblick UJ, Bündgen NK, Nicorici D, et al. The gene expression signature of genomic instability in breast cancer is an independent predictor of clinical outcome. Int J Cancer 2009;124:1552-64.
9. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy- refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010;11:753-62.
10. Tsafrir D, Bacolod M, Selvanayagam Z, Tsafrir I, Shia J, Zeng Z, et al. Relationship of gene expression and chromosomal abnormalities in colorectal cancer. Cancer Res 2006;66:2129-37.
11. Huitink JM, Heimerikxs M, Nieuwland M, Loer SA, Brugman W, Velds A, et al. Volatile anesthetics modulate gene expression in breast and brain tumor cells. Anesth Analg 2010;111:1411-5.
12. Opitz L, Salinas-Riester G, Grade M, Jung K, Jo P, Emons G, et al. Impact of RNA degradation on gene expression profiling. BMC Med Genomics 2010;3:36.
13. van de Wiel MA, Picard F, van Wieringen WN, Ylstra B. Preprocessing and downstream analysis of microarray DNA copy number profiles. Brief Bioinform 2010.
14. Brosens RP, Haan JC, Carvalho B, Rustenburg F, Grabsch H, Quirke P, et al. Candidate driver genes in focal chromosomal aberrations of stage II colon cancer. J Pathol 2010;221:411-24.
15. Devries S, Nyante S, Korkola J, Segraves R, Nakao K, Moore D, et al. Array-based comparative genomic hybridization from formalin-fixed, paraffin-embedded breast tumors. J Mol Diagn 2005;7:65-71. (Pubitemid 40310167)
16. Andre F, Job B, Dessen P, Tordai A, Michiels S, Liedtke C, et al. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res 2009;15:441-51.
17. Bergamaschi A, Kim YH, Wang P, Sørlie T, Hernandez-Boussard T, Lonning PE, et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and geneexpression subtypes of breast cancer. Genes Chromosomes Cancer 2006;45:1033-40. (Pubitemid 44435537)
18. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006;10:529-41. (Pubitemid 44854748)
19. Leary RJ, Lin JC, Cummins J, Boca S, Wood LD, Parsons DW, et al. Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci U S A 2008;105:16224-9.
20. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006;7:96.
21. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
22. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74. (Pubitemid 32878711)
23. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009;360:790-800.
24. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27:1160-7.
25. van Wieringen WN, van de Wiel MA. Nonparametric testing for DNA copy number induced differential mRNA gene expression. Biometrics 2009;65:19-29.
26. van de Wiel MA, van Wieringen WN. CGHregions: Dimension Reduction for Array CGH Data with Minimal Information Loss. Cancer Inform 2007;3:55-63.
27. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010;463:899-905.
28. Tan PK, Downey TJ, Spitznagel EL Jr., Xu P, Fu D, Dimitrov DS, et al. Evaluation of gene expression measurements from commercial microarray platforms. Nucleic Acids Res 2003;31:5676-84. (Pubitemid 37441938)
29. Schweiger MR, Kerick M, Timmermann B, Albrecht MW, Borodina T, Parkhomchuk D, et al. Genome-wide massively parallel sequencing of formaldehyde fixed-paraffin embedded (FFPE.tumor tissues for copy-number- and mutation-analysis. PLoS One 2009;4:e5548.
30. Wood HM, Belvedere O, Conway C, Daly C, Chalkley R, Bickerdike M, et al. Using next-generation sequencing for high resolution multiplex analysis of copy number variation from nanogram quantities of DNA from formalin-fixed paraffin-embedded specimens. Nucleic Acids Res 2010;38:e151.
31. van Wieringen WN, van de Wiel MA, Ylstra B. Weighted clustering of called array CGH data. Biostatistics 2008;9:484-500. (Pubitemid 351882087)
32. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 2006;100: 229-35. (Pubitemid 44631925)